Agents targeting programmed cell death 1 protein (PD-1) or its ligand (PD-L1) have demonstrated exceptional, often durable response rates (approaching 50%), which translate to improved survival among cSCC patients in the advanced disease setting.6 These findings led to U.S. Food and Drug Administration (FDA) approval of cemiplimab (an anti-PD-1 agent) in September 2018. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.